Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23107524 | 0.86 | KDM4E (0.40) | KMT2AKDM4ECCR1CCR5CCR8 | |
| SCHEMBL22521660 | 0.84 | GRIN2B (0.43) | GRIN2B | |
| SCHEMBL6219117 | 0.81 | ENPP3 (0.49) | GRIN2BKMT2ARHEBNOTUMFPR2 | |
| SCHEMBL30052421 | 0.81 | PARP1 (0.40) | KMT2AALDH1A1MAPTRHEBNOTUM | |
| SCHEMBL23885229 | 0.81 | PARP1 (0.40) | KMT2AALDH1A1MAPTRHEBNOTUM | |
| SCHEMBL29781672 | 0.81 | ENPP3 (0.49) | GRIN2BKMT2ARHEBNOTUMFPR2 | |
| SCHEMBL13145589 | 0.81 | KMT2A (0.36) | KMT2AKDM4EALDH1A1POLBMAPT | |
| SCHEMBL25526559 | 0.80 | FPR2 (0.41) | KMT2AKDM4EALDH1A1FPR2 | |
| SCHEMBL23107317 | 0.78 | CCR1 (0.41) | KMT2AKDM4ECCR1CCR5CCR8 | |
| SCHEMBL15157352 | 0.77 | KMT2A (0.44) | KMT2AKDM4EALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | GRIN2B 1372/4885KMT2A 2576/4885KDM4E 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.